Versus Gemcitabine(与吉西他滨相比)研究综述
Versus Gemcitabine 与吉西他滨相比 - Another subgroup analysis was performed based on chemotherapy regimen: Fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) versus Gemcitabine and Abraxane. [1]根据化疗方案进行另一亚组分析:氟尿嘧啶、亚叶酸、奥沙利铂和伊立替康 (FOLFIRINOX) 与吉西他滨和 Abraxane。 [1]
Chemotherapy Versus Gemcitabine
A fifth trial compared postoperative adjuvant S-1 (a novel oral fluoropyrimidine derivative) chemotherapy versus gemcitabine in 70 participants with intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma (64 participants), and gallbladder carcinoma (6 participants). [1] We investigated the efficacy of first‐line gemcitabine and cisplatin (GP) chemotherapy versus gemcitabine and cisplatin chemotherapy combined with the anti‐angiogenic drug endostar (GP + E) in advanced thymoma and thymic carcinoma. [2] Here, we have evaluated the efficacy of intensified chemotherapy versus gemcitabine monotherapy in real-life settings across Europe. [3]第五项试验在 70 名肝内胆管癌、肝门周围胆管癌(64 名参与者)和胆囊癌(6 名参与者)的参与者中比较了术后辅助 S-1(一种新型口服氟嘧啶衍生物)化疗与吉西他滨。 [1] 我们研究了一线吉西他滨和顺铂 (GP) 化疗与吉西他滨和顺铂化疗联合抗血管生成药物恩度 (GP + E) 在晚期胸腺瘤和胸腺癌中的疗效。 [2] 在这里,我们评估了强化化疗与吉西他滨单药治疗在欧洲现实生活环境中的疗效。 [3]
Erlotinib Versus Gemcitabine
The North Central Cancer Treatment Group (now part of Alliance for Clinical Trials in Oncology) trial N064B compared gemcitabine plus erlotinib versus gemcitabine plus combined EGFR inhibition with erlotinib and panitumumab. [1] PATIENTS AND METHODS This was a multicenter (17 centers in China), open-label, phase II, randomized controlled trial of erlotinib versus gemcitabine plus cisplatin (GC chemotherapy) as neoadjuvant/adjuvant therapy in patients with stage IIIA-N2 non-small-cell lung cancer with EGFR mutations in exon 19 or 21 (EMERGING). [2]中北部癌症治疗组(现在是肿瘤临床试验联盟的一部分)试验 N064B 比较了吉西他滨加厄洛替尼与吉西他滨加联合 EGFR 抑制与厄洛替尼和帕尼单抗。 [1] 患者和方法 这是一项多中心(中国 17 个中心)、开放标签、II 期、随机对照试验,厄洛替尼对比吉西他滨加顺铂(GC 化疗)作为 IIIA-N2 期非小细胞肺癌患者的新辅助/辅助治疗EGFR 外显子 19 或 21 突变(新兴)。 [2]
Mfolfirinox Versus Gemcitabine
Patients with an elevated SIRI treated with mFOLFIRINOX versus gemcitabine plus nab-paclitaxel and gemcitabine showed a clinically and statistically significant difference in median OS of 17 months compared to 6 and 4 months respectively (p < 0. [1] Indirect DFS comparison demonstrated superiority of mFOLFIRINOX versus gemcitabine-capecitabine, gemcitabine-erlotinib and gemcitabine-nab-paclitaxel. [2]mFOLFIRINOX 与吉西他滨联合白蛋白结合型紫杉醇和吉西他滨治疗的 SIRI 升高的患者在 17 个月与 6 个月和 4 个月的中位 OS 方面分别显示出临床和统计学上的显着差异(p < 0. [1] 间接 DFS 比较表明 mFOLFIRINOX 优于吉西他滨-卡培他滨、吉西他滨-厄洛替尼和吉西他滨-白蛋白-紫杉醇。 [2]
Gemcitabine Versus Gemcitabine
Type of chemotherapy was not predictive of overall survival (HR for gemcitabine versus gemcitabine plus capecitabine: 1. [1] Part A of the study was an intrapatient dose escalation lead-in portion in patients concurrently receiving gemcitabine, and in part B, patients were randomized 1: 1 to the recommended phase 2 dose combination PCI-27483–gemcitabine versus gemcitabine alone. [2]化疗类型不能预测总生存期(吉西他滨与吉西他滨加卡培他滨的 HR:1. [1] 研究的 A 部分是同时接受吉西他滨的患者的患者内剂量递增导入部分,在 B 部分中,患者按 1:1 随机分配至推荐的 2 期剂量组合 PCI-27483-吉西他滨与单独使用吉西他滨。 [2]
versus gemcitabine plu 与吉西他滨 Plu
Type of chemotherapy was not predictive of overall survival (HR for gemcitabine versus gemcitabine plus capecitabine: 1. [1] Methods: This was a multicenter (17 centers in China) phase II randomized controlled trial of erlotinib(E)versus gemcitabine plus cisplatin (GC) as neoadjuvant/adjuvant therapy in pts with stage IIIA-N2 NSCLC with EGFR mutations in exon 19 or 21. [2] The North Central Cancer Treatment Group (now part of Alliance for Clinical Trials in Oncology) trial N064B compared gemcitabine plus erlotinib versus gemcitabine plus combined EGFR inhibition with erlotinib and panitumumab. [3] PATIENTS AND METHODS This was a multicenter (17 centers in China), open-label, phase II, randomized controlled trial of erlotinib versus gemcitabine plus cisplatin (GC chemotherapy) as neoadjuvant/adjuvant therapy in patients with stage IIIA-N2 non-small-cell lung cancer with EGFR mutations in exon 19 or 21 (EMERGING). [4] Patients with an elevated SIRI treated with mFOLFIRINOX versus gemcitabine plus nab-paclitaxel and gemcitabine showed a clinically and statistically significant difference in median OS of 17 months compared to 6 and 4 months respectively (p < 0. [5]化疗类型不能预测总生存期(吉西他滨与吉西他滨加卡培他滨的 HR:1. [1] 方法:这是一项多中心(中国 17 个中心)的 II 期随机对照试验,厄洛替尼(E)与吉西他滨联合顺铂(GC)作为新辅助/辅助治疗 IIIA-N2 期 NSCLC 患者,EGFR 外显子 19 或 21 突变. [2] 中北部癌症治疗组(现在是肿瘤临床试验联盟的一部分)试验 N064B 比较了吉西他滨加厄洛替尼与吉西他滨加联合 EGFR 抑制与厄洛替尼和帕尼单抗。 [3] 患者和方法 这是一项多中心(中国 17 个中心)、开放标签、II 期、随机对照试验,厄洛替尼对比吉西他滨加顺铂(GC 化疗)作为 IIIA-N2 期非小细胞肺癌患者的新辅助/辅助治疗EGFR 外显子 19 或 21 突变(新兴)。 [4] mFOLFIRINOX 与吉西他滨联合白蛋白结合型紫杉醇和吉西他滨治疗的 SIRI 升高的患者在 17 个月与 6 个月和 4 个月的中位 OS 方面分别显示出临床和统计学上的显着差异(p < 0. [5]
versus gemcitabine alone
6, a phase III, multicenter, randomized clinical trial of postoperative leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) versus gemcitabine alone, presented at the 2018 ASCO Annual Meeting. [1] Two recently published trials evaluated the role of combination therapies for resected pancreatic cancer and demonstrated better outcomes with a gemcitabine and capecitabine combination and a fluorouracil, oxaliplatin, and irinotecan combination (FOLFIRINOX) versus gemcitabine alone. [2] Part A of the study was an intrapatient dose escalation lead-in portion in patients concurrently receiving gemcitabine, and in part B, patients were randomized 1: 1 to the recommended phase 2 dose combination PCI-27483–gemcitabine versus gemcitabine alone. [3]在 2018 年 ASCO 年会上发表的一项关于术后亚叶酸钙、氟尿嘧啶、盐酸伊立替康和奥沙利铂 (FOLFIRINOX) 与单独使用吉西他滨的 III 期、多中心、随机临床试验。 [1] 最近发表的两项试验评估了联合疗法对切除胰腺癌的作用,并证明吉西他滨和卡培他滨联合以及氟尿嘧啶、奥沙利铂和伊立替康联合 (FOLFIRINOX) 与单独吉西他滨相比具有更好的结果。 [2] 研究的 A 部分是同时接受吉西他滨的患者的患者内剂量递增导入部分,在 B 部分中,患者按 1:1 随机分配至推荐的 2 期剂量组合 PCI-27483-吉西他滨与单独使用吉西他滨。 [3]
versus gemcitabine monotherapy
Here, we have evaluated the efficacy of intensified chemotherapy versus gemcitabine monotherapy in real-life settings across Europe. [1] We performed this systematic review and meta-analysis of clinical randomized phase III trials to explore the efficacy and safety of gemcitabine plus anti-angiogenesis therapy versus gemcitabine monotherapy for locally advanced or metastatic pancreatic cancer. [2]在这里,我们评估了强化化疗与吉西他滨单药治疗在欧洲现实生活环境中的疗效。 [1] 我们对临床随机 III 期试验进行了系统回顾和荟萃分析,以探索吉西他滨联合抗血管生成治疗与吉西他滨单药治疗局部晚期或转移性胰腺癌的疗效和安全性。 [2]